Iovance Biotherapeutics, Inc. revenue by segment IOVA

Annual Quarterly

Iovance Biotherapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Amtagvi at $220.0 million, 83% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
379
264
164
1
—
—
—
—
0
0
0
Amtagvi
—
220
+112.4%
share 83.5%
104
share 63.1%
—
—
—
—
—
—
—
—
Proleukin
—
43
-28.1%
share 16.5%
61
+4988.6%
share 36.9%
1
share 100.0%
—
—
—
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IOVA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Carlos, CA
SEC filer status
Accelerated filer
SEC CIK
1425205
Former names
Lion Biotechnologies, Inc. (until Jun 5, 2017); Genesis Biopharma, Inc (until Sep 23, 2013); FREIGHT MANAGEMENT CORP (until Mar 8, 2010)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.